Agomelatine facilitates positive versus negative affective processing in healthy volunteer models

Area of Science:

• Neuroscience
• Psychopharmacology
• Affective Science

Background:

• Agomelatine is a novel antidepressant with a unique pharmacological profile.
• Clinical efficacy is established for major depression, but its effects on emotional processing are unknown.
• Conventional antidepressants can sometimes lead to emotional blunting.

Purpose of the Study:

• To assess the effect of agomelatine on emotional processing in healthy volunteers.
• To investigate agomelatine's impact on facial expression recognition, emotional memory, and attentional bias.
• To compare agomelatine's effects with placebo and its potential for selective emotional processing modulation.

Main Methods:

• A double-blind, parallel-group study involving 48 healthy volunteers.
• Randomized assignment to placebo, 25 mg, or 50 mg of agomelatine for 7 days.
• Assessment using the Emotional Test Battery (facial recognition, emotional memory, attentional probe, emotion-potentiated startle) on day 8.

Main Results:

• Agomelatine (25 mg) significantly decreased subjective sadness ratings.
• Reduced recognition of sad facial expressions and improved positive affective memory were observed.
• A reduction in the emotion-potentiated startle response was noted with 25 mg agomelatine.

Conclusions:

• Agomelatine demonstrates selective effects on processing social facial cues, potentially offering an advantage over conventional antidepressants.
• These selective effects may contribute to a reduced experience of emotional blunting.
• Volunteer models are valuable for screening and profiling novel antidepressant candidates.